Overview: Jo-1 Antibody TestIntroduction: The Jo-1 Antibody Test detects Jo-1 antibodies to diagnose autoimmune diseases like polymyositis, causing muscle weakness. Following 2023 ACR guidelines, it uses immunoassay for high specificity, supporting autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected polymyositis or dermatomyositis.
Other Names: Jo-1 Ab Assay, Polymyositis Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Jo-1 antibody testing began in the 1980s with myositis research. Immunoassay-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Jo-1 antibodies to diagnose polymyositis or dermatomyositis, guides treatment, and evaluates patients with muscle weakness.
Test Parameters: 1. Jo-1 Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of muscle weakness, rash, or joint pain.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document muscle weakness, rash, joint pain, or family history of autoimmune diseases. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, autoimmune implications, and risks of blood or saliva collection.
Procedural Considerations: Uses immunoassay to detect Jo-1 antibodies in serum or saliva. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for myositis diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Positive Jo-1 antibodies confirm polymyositis or dermatomyositis, guiding immunosuppressive therapy. Negative results may require further autoimmune testing.
Specialist Consultation: Consult a rheumatologist for result interpretation and treatment planning.
Additional Supporting Tests: ANA, CK levels, or muscle biopsy to confirm myositis diagnosis.
Test Limitations: Not specific to polymyositis; other myopathies may produce Jo-1 antibodies. Clinical correlation is needed.
References: ACR Myositis Guidelines, 2023; Arthritis & Rheumatology, Miller FW, 2022.
